Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

CJS Securities Downgrades John Wiley & Sons to Market Perform

CJS Securities analyst Daniel Moore downgrades John Wiley & Sons (NYSE:WLY) from Market Outperform to Market Perform.
byBenzinga Newsdesk
August 29, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

CJS Securities analyst Daniel Moore downgrades John Wiley & Sons (NYSE:WLY) from Market Outperform to Market Perform.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AstraZeneca Announced Calquence Approved in Japan for Adults with Treatment Naïve Chronic Lymphocytic Leukaemia

By Charles Gross
December 28, 6:15 AM
AstraZeneca's Calquence (acalabrutinib), a selective Bruton's tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with treatment-naïve chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL]). Calquence was previously approved in Japan for the treatment of adults with relapsed or refractory CLL.

AZN